Protein Supplementation Does Not Augment Adaptations to Endurance Exercise Training

Kristin L Jonvik¹, Kevin JM Paulussen¹, Shiannah L Danen¹, Ingrid JM Ceelen¹, Astrid M Horstman³, Floris C Wardenaar¹, Luc JC van Loon¹,², Jan-Willem van Dijk¹

¹Institute of Sports and Exercise Studies, HAN University of Applied Sciences, Nijmegen, the Netherlands; ²Department of Human Biology, NUTRIM, Maastricht University Medical Centre+, the Netherlands; ³FrieslandCampina, Amersfoort, the Netherlands

Accepted for Publication: 22 April 2019
Protein Supplementation Does Not Augment Adaptations to Endurance Exercise Training

Kristin L Jonvik1*, Kevin JM Paulussen1*, Shiannah L Danen1, Ingrid JM Ceelen1, Astrid M Horstman3, Floris C Wardenaar1, Luc JC van Loon1,2, Jan-Willem van Dijk1

1Institute of Sports and Exercise Studies, HAN University of Applied Sciences, Nijmegen, the Netherlands; 2Department of Human Biology, NUTRIM, Maastricht University Medical Centre+, the Netherlands; 3FrieslandCampina, Amersfoort, the Netherlands

* These authors contributed equally to this work

Address for correspondence

Dr. Jan-Willem van Dijk
Institute of Sports and Exercise Studies
HAN University of Applied Sciences
PO Box 6960
6503 GL Nijmegen
The Netherlands
Tel: +(31) 6 55227849
Email: janwillem.vandijk@han.nl
This project was funded by the Dutch Ministry of Economic Affairs (Topsector Agri&Food), award number: AF16501 (PPS Allowance). KLJ, KJMP, SLD and IJMC declare that they have no conflict of interest. FCW, LJCvL and JWvD have received research grants, consulting fees, and/or speaking honoraria from FrieslandCampina. LJCvL has received research grants, consulting fees, and speaking honoraria from Pepsico/Gatorade. AMHH is an employee at FrieslandCampina.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American College of Sports Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
ABSTRACT

Introduction: Recently, it has been speculated that protein supplementation may further augment the adaptations to chronic endurance exercise training. We assessed the impact of protein supplementation during chronic endurance exercise training on whole-body oxidative capacity (VO$_{2\max}$) and endurance exercise performance.

Methods: In this double-blind, randomized, parallel placebo-controlled trial, sixty recreationally active males (age: 27±6 y; BMI: 23.8±2.6 kg·m$^{-2}$; VO$_{2\max}$: 47±6 mL·min$^{-1}$·kg$^{-1}$) were subjected to 12 weeks of triweekly endurance exercise training. After each session and each night before sleep, participants ingested either a protein supplement (PRO; 28.7 g casein protein) or an isoenergetic carbohydrate placebo (PLA). Before and after the 12 weeks of training, VO$_{2\max}$ and endurance exercise performance (~10-km time-trial) were assessed on a cycle ergometer. Muscular endurance (total workload achieved during 30 reciprocal isokinetic contractions) was assessed by isokinetic dynamometry and body composition by DXA. Mixed-model ANOVA was applied to assess whether training adaptations differed between groups.

Results: Endurance exercise training induced an 11±6% increase in VO$_{2\max}$ (time effect, $P<0.0001$), with no differences between groups (PRO: 48±6 to 53±7 mL·min$^{-1}$·kg$^{-1}$; PLA: 46±5 to 51±6 mL·min$^{-1}$·kg$^{-1}$; time×treatment interaction, $P=0.50$). Time to complete the time-trial was reduced by 14±7% (time effect, $P<0.0001$), with no differences between groups (time×treatment interaction, $P=0.15$). Muscular endurance increased by 6±7% (time effect, $P<0.0001$), with no differences between groups (time×treatment interaction, $P=0.84$). Leg lean mass showed an increase following training ($P<0.0001$), which tended to be greater in PRO compared with PLA (0.5±0.7 vs 0.2±0.6 kg, respectively; time×treatment interaction, $P=0.073$).
Conclusion: Protein supplementation after exercise and before sleep does not further augment the gains in whole-body oxidative capacity and endurance exercise performance following chronic endurance exercise training in recreationally active, healthy young males.

Key words: VO2max, endurance exercise, endurance performance, muscular endurance, strength, protein intake
INTRODUCTION

Maximum oxygen uptake (VO\textsubscript{2max}) can be defined as the highest rate at which oxygen can be taken up and utilized by the body during strenuous exercise (1). As the VO\textsubscript{2max} is fundamental to endurance exercise performance, many athletes aim to improve their VO\textsubscript{2max} by endurance exercise training. Indeed, continuous endurance exercise and interval training have been shown effective in improving VO\textsubscript{2max} and endurance performance (2).

Along with endurance exercise training, nutrition plays an important role with regard to endurance exercise performance. Carbohydrate ingestion and endogenous carbohydrate storage have been linked to endurance exercise performance, as carbohydrates are the main fuel source during moderate-to-high intensity endurance exercise (3). Over the past few years, there has been an increasing interest in the role of protein ingestion during and after endurance exercise to support physiological training adaptations (4, 5). The proposed increased protein requirements induced by endurance exercise have been attributed to multiple factors, such as increased rates of protein oxidation during (6) and after (7) endurance exercise, and haematological, vascular, and skeletal muscle adaptations induced by endurance exercise training (5). Furthermore, acute protein supplementation has been shown to augment the muscle protein synthetic response to endurance exercise (8-12). Taken together, it can be speculated that chronic protein supplementation enhances recovery and facilitates the adaptive response to endurance exercise training. Although the importance of dietary protein ingestion in relation to muscle mass and strength following chronic resistance exercise training has been well established (13), the role of dietary protein in relation to chronic endurance exercise training remains to be elucidated. To the best of our knowledge, only two studies have investigated the effects of protein supplementation on endurance exercise-induced training adaptations. Robinson et al. (14) reported that healthy older adults achieved greater improvements in VO\textsubscript{2max} after 6 weeks of endurance exercise training when protein was supplemented. In line with these findings, Ferguson-Stegall et al. (15)
reported that healthy young subjects attained greater improvements in VO$_{2\text{max}}$ following post-exercise supplementation with chocolate milk (carbohydrate-protein mixture) as opposed to placebo during 4.5 weeks of endurance exercise training. Although these results suggest that protein supplementation may augment the adaptive response to chronic endurance exercise training, the aforementioned studies were conducted in small cohorts and performance measures were not included. Clearly, more research is warranted to establish the proposed benefits of protein supplementation for the adaptive response to chronic endurance exercise training.

In the current study, we aimed to assess the impact of protein supplementation on the increase in VO$_{2\text{max}}$ and endurance exercise performance induced by chronic endurance exercise training. For this purpose, sixty healthy young males were subjected to 12 weeks of endurance exercise training, comprising three exercise sessions weekly. After each training session and each night before sleep, participants ingested either a protein supplement (28.7 g casein protein) or an isoenergetic carbohydrate placebo. We hypothesized that supplementation with protein as opposed to a placebo leads to greater improvements in VO$_{2\text{max}}$ and endurance exercise performance following 12 weeks of endurance exercise training.

METHODS

Study design and setting

We conducted a 12-week double blind, randomized, placebo-controlled trial with a parallel group design. Participants were allocated randomly to either a protein-supplemented exercise intervention group (PRO) or a placebo-supplemented exercise intervention group (PLA). A schematic overview of participant flow is presented as Figure (Supplemental Digital Content 1, CONSORT flow diagram, http://links.lww.com/MSS/B614). The exercise intervention and testing procedures took place at the sport and research centre of the HAN University of Applied Sciences in Nijmegen, the Netherlands between September 2017 and June 2018. The study was approved by the Independent Review Board Nijmegen Medical Ethical Committee, the
Netherlands, and conformed to the standards for the use of human participants as outlined in the most recent version of the Helsinki Declaration. The study was registered at the Netherlands Trial Registry (www.trialregister.nl) as NTR6691.

Participants
Sixty eligible young (18-40 y), non-obese (BMI <30 kg/m\(^2\)), healthy males were recruited through advertising in local newspapers and social media. Exclusion criteria were participation in structural endurance exercise, performing other structured exercise for more than 6 hours per week, and/or a VO\(_{2}\text{max}\) >55 mL/min/kg. After initial screening by telephone, a screening visit was planned. All participants were informed of the nature and possible risks of the experimental procedures before their written informed consent was obtained. Subsequently, medical history was checked and VO\(_{2}\text{max}\) was assessed.

Randomization and blinding
Participants were allocated randomly in a 1:1 ratio to either the protein or placebo group. A computer generated randomization list was made by an independent researcher and shared with the supplement manufacturer. Allocation concealment was ensured by the manufacturer of the supplements, who labelled all protein and placebo supplements according to participant number. The researchers responsible for screening allocated each eligible participant to the next available number on entry into the trial. Block randomization was used with block sizes of 30, as the training program was commenced with two consecutive cohorts of 30 participants (cohort 1: September-December 2017; cohort 2: March-June 2018). All study personnel and participants were blinded to treatment assignment for the duration of the study. The randomization list was revealed to the researchers once recruitment, data collection, and data entry were completed and checked, and the dataset was locked. Participants’ blinding was confirmed through an exit survey. In this regard, 62% guessed the intervention correctly, while 38% guessed the intervention incorrectly.
**Intervention**

**Exercise program**

During a 12-week period, all participants performed three supervised exercise sessions weekly (Mondays, Wednesdays, and Fridays) on a cycle ergometer (Matrix U3X, Matrix Fitness, WI, USA), on a self-selected time between 8:00h and 20:00h. Each Monday, participants performed 6 x 4-min work intervals at a target intensity of 85-90% $HR_{\text{max}}$ interspersed with 4-min active recovery periods. Each Wednesday, participants performed continuous endurance exercise sessions of 60 min at a target intensity of 75-80% $HR_{\text{max}}$. Each Friday, participants performed 3 sets of 6 x 1-min work intervals at a target intensity of 90-95% $HR_{\text{max}}$ interspersed with 1-min active recovery periods and 5 min of active rest between sets. During the first 4 weeks of training, the exercise volume was gradually increased to the full exercise training program described above. All exercise sessions included a 5-min warm-up and cool-down. During all training sessions, verbal encouragement was given by personal trainers, and the heart rate was monitored continuously (Zephyr™ Performance Systems, Medtronic, MD, USA) to verify the prescribed exercise intensity. Training progression was monitored by registration of the selected workload (W) during each exercise session.

**Supplementation**

Throughout the 12-week intervention period, participants consumed 250 mL of either a protein supplement or an isoenergetic carbohydrate placebo immediately following each exercise session and each night before sleep. The protein supplement contained 538 kJ (129 kcal), 28.7 g protein (casein protein), 0.3 g fat and 2.6 g carbohydrate. The isoenergetic placebo supplement contained 541 kJ (129 kcal), 0.6 g protein, 2.4 g fat and 25.8 g carbohydrate. The products were provided in opaque white plastic bottles and could not be discerned by taste (vanilla flavoured), smell, texture, or colour. All products were composed by FrieslandCampina (Amersfoort, the Netherlands) and produced at NIZO (Ede, The Netherlands). Participants received their post-
exercise supplements from the researchers immediately after each training session, whereas the pre-sleep supplements were distributed in cardboard boxes every 2 weeks to take home. Participants were instructed to ingest the pre-sleep supplements each evening within 15 min before bedtime. A supplement log was submitted to the researchers every 2 weeks to verify compliance.

In addition to the PRO or PLA supplement, all participants received a carbohydrate-rich snack after each exercise session (439-678 kJ (105-162 kcal), 27.0-36.3 g carbohydrates, 1.3-1.7 g protein, and 0.4-0.9 g fat) to comply with the nutritional recommendations for endurance exercise and to (partly) compensate for the energy deficit induced by the exercise session.

**Study Procedures**

Before assessing baseline data, participants visited the laboratory twice to become familiarized with the exercise testing procedures (VO$_{2\text{max}}$, time-trial, and muscle function tests). Two weeks before commencing the exercise training program, baseline data were collected during two visits (pretest 1 and 2) separated by at least 48 hours. During pretest 1, participants reported to the laboratory in an overnight fasted state. After measuring blood pressure and venous blood sampling, body composition was assessed by dual energy X-ray absorptiometry (DXA). Participants were then provided breakfast, and at least 30 min later, they performed the VO$_{2\text{max}}$ test. During pretest 2, participants first performed a 10-km time-trial. After a 30 min break, muscle function was assessed by isokinetic dynamometry. The measurements of pretest 1 were repeated 3 to 7 days after completing the last exercise session of the 12-week intervention program (posttest 1), whereas the measurements of pretest 2 were repeated 10-12 days after completing the last exercise session (posttest 2). All testing procedures were conducted on the same time of the day and under the same standardized conditions (i.e. no exercise or alcohol 48 h prior and no caffeine 12 h before testing). In addition, measurements of dietary intake and
habitual physical activity were assessed at baseline, and at week 6 and week 12 of the exercise intervention program.

**Outcomes**

**$VO_{2\text{max}}$**

Participants’ maximal oxygen consumption ($VO_{2\text{max}}$), power output ($W_{\text{max}}$) and heart rate ($HR_{\text{max}}$) were determined while performing an incremental cycling test to exhaustion on an electromagnetically braked cycle ergometer (Lode Excalibur Sport, Groningen, the Netherlands). Oxygen consumption and carbon dioxide production were assessed by an automated spiroergometry system with breath-by-breath gas collection technology (Cortex, Metalyser 3B, Leipzig, Germany). The automated spiroergometry system was calibrated to ambient air before each test. A two-point gas calibration and volume calibration was performed daily and after 3 consecutive tests. After an initial warm-up of 5 min at 75 W, workload was increased progressively with 25 W·min$^{-1}$ until the participant reached volitional exhaustion. $VO_{2\text{max}}$ was defined as the mean of the highest consecutive $VO_2$ values over 30 s, and verified by using the $VO_{2\text{max}}$ attainment criteria, including the detection of a $VO_2$ plateau, lack of increase in heart rate with continued increase in workload, and a $RER >1.10$ (16). $W_{\text{max}}$ was defined as the power reached at exhaustion. $HR_{\text{max}}$ was defined as the highest heart rate achieved during the test.

**Time-trial**

Participants performed a simulated ~10-km cycling time-trial on an electromagnetically braked cycle ergometer (Lode Excalibur Sport, Groningen, the Netherlands) to assess endurance performance. The amount of work to be performed was calculated as follows: total amount of work (J) = 0.85 * $W_{\text{max}}$ * 900 (s) (17). The ergometer was set in linear-mode in which 85% $W_{\text{max}}$ was achieved when participants cycled at their preferred pedalling rate as determined during the familiarization sessions. Participants received no verbal encouragement or visible information on elapsed time and pedalling rate throughout the time-trial, but were aware of the absolute (kJ) and
relative (%) amount of work completed. The absolute work target (kJ) and linear-mode settings were kept similar between pre- and posttesting to allow for comparison of time to completion.

**Muscle function**

Isometric and isokinetic testing of the upper right leg were performed on a dynamometer (Humac Norm Isokinetic Extremity System, CSMI, Stoughton MA, USA). Participants were placed in an upright seated position with the back-chair seat set to an angle of 85° and fastened to the seat and lever arm of the dynamometer by torso, thigh and shin straps to reduce contribution of any irrelevant body movement. The dynamometer was adjusted so that the femoral epicondyle was in line with the axis of rotation of the lever arm. Three maximal voluntary isometric knee extensions were performed for a duration of 4 s at a knee angle of 60° with 1-min rest intervals between successive attempts. Subsequently, maximal voluntary isokinetic knee extension and flexion were determined at angular velocities of 90 and 180°/s. At both velocities, 5 reciprocal contractions were performed. For each maximal strength test, the single best contraction was used for analyses. Finally, isokinetic muscular endurance was determined by 30 reciprocal contractions at an angular velocity of 180 °/s. Participants were instructed and verbally encouraged to execute each contraction with maximal force and were given verbal feedback on the number of repetitions. Between each different test, participants rested for 90 s. All isokinetic tests were performed over an 85° range of motion with the knee fully extended being 0°. Analyses were performed over a 10-75° range of motion to dismiss any end-range deceleration. Data were generated using the Humac Norm system’s software package and MATLAB (Mathworks, Natick MA, USA).

**Body composition**

Participants’ body mass and height were determined using a digital scale and a mobile stadiometer, respectively (Seca 770 and Seca 213i, Hamburg, Germany). Whole-body and regional body composition were measured by DXA (Horizon W, Hologic, MA, USA) and
determined using the system’s software package (Apex version 5.6.0.5) using the classic calibration algorithm.

*Dietary intake and physical activity*

Habitual dietary intake was assessed during 3 days at baseline, week 6 and week 12 using a web-based 24-hour recall system (Compl-eat, Wageningen University, Wageningen, The Netherlands), as described previously (18). Each 3-day period comprised two weekdays (training and rest day) and one weekend day. The recall days were randomly selected and not announced to the participants. Physical activity was assessed during 7 successive days at baseline, week 6 and week 12 using a wrist-worn physical activity monitor (GT9X Link, Actigraph, Pensacola, FL, USA). The physical activity monitor was worn on the non-dominant wrist and measured physical activity for 24 hours per day during the 7-day measuring period. The sampling frequency was 30 Hz and data was stored in 10-second epochs. Physical activity data were used to assess the percentage of time spent sedentary or at, light, moderate, and vigorous physical activity according to the Freedson classification (19).

*Sample Size and Statistical Analysis*

Sample size was calculated using GPower version 3.1.9.2. (20). Based on the effect of protein supplementation on improvements in VO$_{2\text{max}}$ reported by Ferguson-Stegall et al. (15), we assumed an increase in VO$_{2\text{max}}$ of 5% in the control group and 10% in the protein supplemented group. With 0.8 power to detect a significant difference ($P<0.05$, two-sided), 25 participants were required for both groups. Taking a potential dropout of 15% into account, we planned to enrol 30 participants per group.

Prior to hypothesis testing, data were examined for normality. Non–normally distributed variables were logarithmically transformed before analysis. Baseline characteristics were compared by independent sample t-tests. The primary analyses were conducted on participants who completed the study per protocol. The effect of protein supplementation on training
adaptations was assessed by mixed-model design ANOVA with time (pre- vs post training) as a within-subjects factor and treatment (PRO vs PLA) as a between-subjects factor. Statistical significance was set at $P<0.05$. Data are presented as means±SD, and analysed using SPSS 22.0 (IBM Corp., Armonk, NY, USA). Performance and body composition data were also examined by calculation of Cohen’s $d$ effect size (95%CI).

**RESULTS**

*Participants*

A total of 60 participants were randomized to the 12-week exercise training intervention with supplementation of either placebo ($n=30$) or protein ($n=30$; Supplemental Digital Content 1, CONSORT flow diagram, http://links.lww.com/MSS/B614). Four participants in the placebo group withdrew due to injuries or personal reasons. At baseline, there were no significant differences between the PLA and PRO groups in participants’ characteristics (Table 1), training workload (Table 2), muscular strength (Table 3) and dietary intake (Table 4).

*Compliance*

With 97±4 and 96±3%, training attendance was comparable between PLA and PRO ($P=0.77$). Both groups achieved comparable progression in selected workload over the 12-week intervention period (time×treatment interaction, $P>0.35$; Table 2). Compliance with the nutritional supplement was 98±2 and 97±2% for PLA and PRO, respectively ($P=0.17$).

*Whole-body oxidative capacity and performance*

The intervention induced an 11% increase in VO$_{2\text{max}}$ (time effect, $P<0.0001$), with no differences between treatments (PLA: 46±5 to 51±6 mL·min$^{-1}$·kg$^{-1}$, PRO: 48±6 to 53±7 mL·min$^{-1}$·kg$^{-1}$, time×treatment interaction, $P=0.50$; Figure 1). In line, $W_{\text{max}}$ during the incremental cycling test increased by 11% (time effect, $P<0.0001$), with no differences between treatments (PLA: 4.09±0.50 to 4.51±0.56 W·kg$^{-1}$, PRO: 4.25±0.56 to 4.75±0.64 W·kg$^{-1}$, time×treatment interaction, $P=0.22$). HR$_{\text{max}}$ did not change over time ($P=0.94$), nor did it differ between
treatments (PLA: 190±11 to 190±10 bpm, PRO: 191±8 to 191±7 bpm, time×treatment interaction, \( P=0.94 \)). Although RER\(_{\text{max}}\) significantly decreased over time (\( P=0.010 \)), no differences were observed between treatments (PLA: 1.18±0.06 to 1.16±0.04, PRO: 1.19±0.05 to 1.17±0.05, time×treatment interaction, \( P=0.92 \)).

The 12-week intervention successfully improved time-trial performance, as evidenced by a 14% reduction in time to completion (time effect, \( P<0.0001 \)). No differences were observed between treatments (PLA: 1045±68 to 913±60 s, PRO: 1070±95 to 904±67 s, time×treatment interaction, \( P=0.15 \); Figure 2A). In line, average power output throughout the time-trial increased by 16% (time effect, \( P<0.0001 \)) with no differences between treatments (PLA: 3.02±0.47 to 3.47±0.49 W·kg\(^{-1}\), PRO: 3.06±0.49 to 3.61±0.53 W·kg\(^{-1}\), time×treatment interaction, \( P=0.28 \)).

Estimated mean differences between interventions and effect sizes for VO\(_{\text{2max}}\) and time-trial performance are presented as Table (Supplemental Digital Content 2, Estimated mean differences and effect sizes for performance outcomes and body mass, http://links.lww.com/MSS/B615).

Muscular strength and endurance

The effects of the 12-week intervention on muscular strength are presented in Table 3. A significant time×treatment interaction (\( P=0.015 \)) was detected for maximal isometric torque, which can be explained by marginal increase over time in PLA group (7±29 Nm) along with a marginal decrease in the PRO group (-10±21 Nm). Maximal voluntary isokinetic contraction of the knee extensors showed an increase over time at a velocity of 180°·s\(^{-1}\) (\( P=0.017 \)), but not at a velocity of 90°·s\(^{-1}\) (\( P=0.65 \)), without any differences between treatment (time×treatment interactions, \( P>0.58 \) for all).

Muscular endurance, defined as the total work performed during 30 reciprocal isokinetic contractions, increased by 6% (time effect, \( P<0.0001 \)), with no difference between treatments.
Estimated mean differences between interventions and effect sizes for muscular strength and endurance are presented as Table (Supplemental Digital Content 2, Estimated mean differences and effect sizes for performance outcomes and body mass, http://links.lww.com/MSS/B615).

**Body composition**

Body composition data are presented in Table 1. Although whole-body lean mass (LM) did not change over time ($P=0.097$), a significant increase in leg LM was observed (time effect, $P<0.0001$, Figure 2C). The increase in leg LM in the PRO group (0.5±0.7 kg) tended to be greater when compared with the PLA group (0.2±0.6 kg), although this finding did not reach statistical significance (time×treatment interaction, $P=0.073$). In line, the increase in leg LM showed a small-to-moderate effect size ($ES \ 0.49$) in favour of protein supplementation (Supplemental Digital Content 2, Estimated mean differences and effect sizes for performance outcomes and body mass, http://links.lww.com/MSS/B615).

There was a significant decrease in total fat mass (FM) over time ($P=0.002$), with no differences between PLA and PRO (-0.7±1.4 and -0.4±1.2 kg, respectively, time×treatment interaction, $P=0.43$).

**Dietary intake and physical activity**

Table 4 presents the dietary intake at baseline, week 6, and week 12 of the intervention. In the PRO group, the daily protein intake increased from 1.21±0.35 at baseline to 1.58±0.31 g·kg$^{-1}$ body mass at week 12, whereas no changes were observed in the PLA group (1.25±0.41 to 1.19±0.31 g·kg$^{-1}$ body mass, time×treatment interaction, $P<0.0001$). In contrast, the increase in carbohydrate intake tended to be greater in PLA when compared with PRO, although this interaction did not reach statistical significance (time×treatment interaction, $P=0.091$). There were no changes in energy intake over time ($P=0.14$) or between treatments (time×treatment interaction, $P=0.14$).
interaction, $P=0.91$). There were no changes in habitual activity over time or differences between PLA and PRO groups (Supplemental Digital Content 3, Habitual physical activity level, http://links.lww.com/MSS/B616).

**DISCUSSION**

The current study was designed to assess the impact of protein supplementation on adaptations to chronic endurance exercise training in recreationally active, healthy young males. Although the study showed robust improvements in VO$_{2\text{max}}$, 10-km time-trial performance, and muscular endurance following 12 weeks of endurance exercise training, these adaptations were not further augmented by supplementing ~30 g of protein after exercise and before sleep.

The current study confirms the impact of chronic endurance exercise training on VO$_{2\text{max}}$. The observed improvements in VO$_{2\text{max}}$ (~5 mL·min$^{-1}$·kg$^{-1}$$; \sim11\%$) are in line with the improvements in VO$_{2\text{max}}$ reported in the meta-analysis of Milanovic et al. (2). Noteworthy is the fact that each individual participant in the current study showed an increase in VO$_{2\text{max}}$ (Figure 1). The robust improvements in VO$_{2\text{max}}$ may be attributed to the tightly controlled exercise training program, comprising a combination of continuous endurance exercise and interval training. Indeed, the inclusion of interval training at higher intensities has been shown superior to strict continuous endurance exercise training to increase VO$_{2\text{max}}$ (2). Along with the improvements in VO$_{2\text{max}}$, the efficacy of the current exercise training program is further evidenced by the ~14% improvement in 10-km time-trial performance. Despite the effective training program, no significant differences in VO$_{2\text{max}}$ and endurance performance were observed between the placebo and protein groups. These findings are in contrast with two previous studies that reported on the impact of protein supplementation on the gains in VO$_{2\text{max}}$ following endurance exercise training (14, 15). Those studies reported a substantial increase in VO$_{2\text{max}}$ in the protein supplemented participants, while the increase in VO$_{2\text{max}}$ appeared to be marginal or even absent in the control groups. Some other differences should be noted as well. When compared with both previous
studies, our participants had a higher training level according to their VO$_{2\text{max}}$, the duration of the training intervention was longer, and protein was supplemented more frequently and in higher doses. In contrast, the duration of exercise sessions was higher in the study of Ferguson-Stegall et al. (15; ~5h weekly) compared with the current study (~3h weekly). Regardless of the differences in study designs, the results of the current study indicate that supplementation with protein does not further augment improvements in whole-body oxidative capacity and endurance performance when an intense training stimulus is being provided in recreationally active, healthy young males.

Besides VO$_{2\text{max}}$ and time-trial performance, the current study assessed the impact of endurance exercise training on muscle strength. Maximal isokinetic strength of the knee flexors and extensors was significantly increased. This finding seems somewhat surprising, as endurance exercise is often associated with blunted gains in hypertrophy and strength when combined with resistance exercise training (21, 22). However, it should be noted that the increase in strength observed in our study, was paralleled by an increase in leg lean mass. It is possible that the increase in leg strength and leg lean mass are attributed largely to the interval component of our exercise training. This type of endurance exercise was included in the exercise training program, as this is a standard component of contemporary endurance exercise training programs. Recently, such an endurance exercise program has been shown to increase leg lean mass following 12 weeks of training (23). In agreement with the benefits of protein supplementation during resistance exercise training (13), our results suggest that protein supplementation has the potential to further increase the gains in lean mass induced by endurance exercise training (small-to-moderate effect size in favour of protein).

Along with the impact on maximal isokinetic strength, we also observed a profound effect of endurance exercise training on muscular endurance, as evidenced by an increase in total work conducted during 30 maximal reciprocal isokinetic contractions (Figure 2B). To the best of our
knowledge, the impact of strictly endurance exercise training on muscular endurance has not been investigated previously. Resistance exercise training with high repetitions and minimal rest between sets is normally seen as the most effective way to improve muscular endurance (24). We speculate that robust improvements in muscular endurance as observed in the current study, result from the relatively high-intensity interval exercise where high workloads were sustained during 1-min periods. As such, this type of endurance exercise training might be an attractive alternative to resistance exercise training to improve muscular endurance. Protein supplementation, however, does not seem to further augment the impact of endurance exercise training on muscular endurance.

The protein supplement used in the current study contained 28.7 g of high-quality casein protein and was ingested following each exercise session and each day before sleep. Hence, the weekly protein dose was ~3 to 4-fold greater than the weekly doses previously applied in the studies of and Fergusson-Stegall et al. (15) and Robinson et al. (14). Ingestion of the protein supplement resulted in an increase in daily protein intake from ~1.2 g·kg⁻¹ body mass at baseline to ~1.6 g·kg⁻¹ body mass during the 12-week intervention period, while the daily protein intake remained at ~1.2 g·kg⁻¹ body mass in the placebo group. Current recommendations for endurance athletes suggest a daily protein intake of 1.2 to maximally 1.7 g·kg⁻¹ body mass (25). As such, the protein intake in the placebo group was in the lower range of the protein intake recommendations for endurance athletes, whereas the protein intake recommendations were covered adequately by participants in the protein group. Along with the increase in daily protein intake, the supplementation of protein was timed strategically, with 28.7 g of protein being ingested after each exercise session and each day before sleep. Such an approach with protein supplementation before sleep has been shown to augment the gains in muscle strength and muscle mass following 12 weeks of resistance exercise training (26). This effect might be attributed to the stimulation of muscle protein synthesis during overnight recovery from resistance exercise (27). Despite the
substantial increase in daily protein intake and strategic timing, we found no additional benefits of protein supplementation on whole-body oxidative capacity and endurance performance following chronic endurance exercise. Hence, a habitual daily protein intake of 1.2 g·kg⁻¹ body mass, as reported by the placebo group, seems sufficient to support adaptations to endurance exercise training in moderately trained individuals performing ~3 h of endurance exercise weekly. It can be speculated that the lack of effect of protein supplementation is related to the relatively low volume and frequency of endurance exercise training applied in the current study. Recent evidence suggests that protein requirements of well-trained endurance athletes, performing higher volumes of endurance exercise training, may be higher than previously assumed (7, 28). In this regard, protein oxidation rates increase when the duration and intensity of an endurance exercise bout increases (5). Furthermore, a higher frequency of exercise sessions allows for less recovery time between successive exercise bouts. Nevertheless, the impact of protein supplementation on endurance capacity and exercise performance in well-trained and elite endurance athletes remains an issue for further investigation.

The current study was designed specifically to assess the impact of protein supplementation during chronic endurance exercise training on whole-body oxidative capacity and endurance performance. Strengths of the current study include the tightly controlled endurance exercise training program, high adherence to the exercise program, high compliance with the intake of supplemental beverages, and extensive assessment of whole-body oxidative capacity and endurance performance. Nevertheless, we should also acknowledge some limitations. First, the study was powered to detect a difference in VO₂max between the placebo and protein group. This does not exclude the possibility for a statistical type 2 error with respect to time-trial performance and muscular strength and endurance. In this regard, it should be noted that most outcomes displayed small to moderate effect sizes in favour of protein supplementation. Secondly, we included a relatively homogenous population of healthy young males. Hence, it is
difficult to generalize our findings to other populations aiming to maximize the adaptive response to endurance exercise, such as females, and well-trained or elite athletes. Thirdly, the endurance exercise training program comprised cycling exercise only, involving mainly concentric exercise of the leg muscles. Other exercise modes may involve more active muscle mass (e.g. rowing or cross-country skiing) or may cause more muscle damage (e.g. running), thereby potentially increasing the protein requirements. Therefore, it remains to be established whether the results obtained in the current study are valid for other exercise modes. Finally, many athletes employ a combination of endurance and resistance exercise, which may hamper maximal adaptations to either type of exercise (21, 22). Therefore, it would be relevant to assess whether protein supplementation may further augment gains in endurance performance and strength during chronic concurrent exercise training.

In conclusion, protein supplementation after exercise and before sleep does not further augment the gains in whole-body oxidative capacity and endurance exercise performance following 12 weeks of endurance exercise training in recreationally active healthy young males.
ACKNOWLEDGMENTS

We would like to thank Nigel Ooms, Celeste Pijnenborg, Niek van Stralen, David Zegers and Irith van Boven for their assistance during the training sessions. We would also like to thank Nicole van Wijk, Mirna Klaiber and Birna Vardardóttir for their help during the nutritional and activity assessments and analyses and Cindy van der Avoort for her assistance during the test days.

The authors’ responsibilities were as follows: JWvD, FCW, LJCvL designed the research; KLJ, KJMP, SLD, IJMC, AMHH conducted the research; KLJ, KJMP analysed the data and performed the statistical analyses; KLJ, KJMP, JWvD wrote the manuscript and hold primary responsibility for the final content; all authors contributed to the interpretation of data and discussion of the manuscript for important intellectual content, and approved the final manuscript. The results of this study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The results of the present study do not constitute endorsement by ACSM.

CONFLICTS OF INTEREST AND SOURCES OF FUNDING

This project was funded by the Dutch Ministry of Economic Affairs (Topsector Agri&Food), award number: AF16501 (PPS Allowance). KLJ, KJMP, SLD and IJMC declare that they have no conflict of interest. FCW, LJCvL and JWvD have received research grants, consulting fees, and/or speaking honoraria from FrieslandCampina. LJCvL has received research grants, consulting fees, and speaking honoraria from Pepsico/Gatorade. AMHH is an employee at FrieslandCampina.
REFERENCES

1. Bassett DR, Howley ET. Limiting factors for maximum oxygen uptake and determinants of endurance performance. *Med Sci Sports Exerc*. 2000;32(1):70–84.

2. Milanović Z, Sporiš G, Weston M. Effectiveness of High-Intensity Interval Training (HIT) and Continuous Endurance Training for VO2max Improvements: A Systematic Review and Meta-Analysis of Controlled Trials. *Sports Med*. 2015;45(10):1469–81.

3. Jeukendrup AE. Nutrition for endurance sports: marathon, triathlon, and road cycling. *J Sports Sci*. 2011;29 Suppl 1:S91–9.

4. Knuiman P, Hopman MTE, Verbruggen C, Mensink M. Protein and the Adaptive Response With Endurance Training: Wishful Thinking or a Competitive Edge? *Front Physiol*. 2018;9:598.

5. Moore DR, Camera DM, Areta JL, Hawley JA. Beyond muscle hypertrophy: why dietary protein is important for endurance athletes. *Appl Physiol Nutr Metab*. 2014;39(9):987–97.

6. Mazzulla M, Parel JT, Beals JW, et al. Endurance Exercise Attenuates Postprandial Whole-Body Leucine Balance in Trained Men. *Med Sci Sports Exerc*. 2017;49(12):2585–92.

7. Kato H, Suzuki K, Bannai M, Moore DR. Protein Requirements Are Elevated in Endurance Athletes after Exercise as Determined by the Indicator Amino Acid Oxidation Method. *PLoS ONE*. 2016;11(6):e0157406.

8. Levenhagen DK, Gresham JD, Carlson MG, Maron DJ, Borel MJ, Flakoll PJ. Postexercise nutrient intake timing in humans is critical to recovery of leg glucose and protein homeostasis. *Am J Physiol Endocrinol Metab*. 2001;280(6):E982–93.
9. Howarth KR, Moreau NA, Phillips SM, Gibala MJ. Coingestion of protein with carbohydrate during recovery from endurance exercise stimulates skeletal muscle protein synthesis in humans. *J Appl Physiol.* 2009;106(4):1394–402.

10. Pasiakos SM, McClung HL, McClung JP, et al. Leucine-enriched essential amino acid supplementation during moderate steady state exercise enhances postexercise muscle protein synthesis. *Am J Clin Nutr.* 2011;94(3):809–18.

11. Bohé J, Low A, Wolfe RR, Rennie MJ. Human muscle protein synthesis is modulated by extracellular, not intramuscular amino acid availability: a dose-response study. *J Physiol.* 2003;552(Pt 1):315–24.

12. Wilkinson SB, Phillips SM, Atherton PJ, et al. Differential effects of resistance and endurance exercise in the fed state on signalling molecule phosphorylation and protein synthesis in human muscle. *J Physiol.* 2008;586(15):3701–17.

13. Cermak NM, Res PT, de Groot LCPGM, Saris WHM, van Loon LJC. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. *Am J Clin Nutr.* 2012;96(6):1454–64.

14. Robinson MM, Turner SM, Hellerstein MK, Hamilton KL, Miller BF. Long-term synthesis rates of skeletal muscle DNA and protein are higher during aerobic training in older humans than in sedentary young subjects but are not altered by protein supplementation. *FASEB J.* 2011;25(9):3240–9.

15. Ferguson-Stegall L, McCleave E, Ding Z, et al. Aerobic exercise training adaptations are increased by postexercise carbohydrate-protein supplementation. *J Nutr Metab.* 2011;2011:623182.
16. Beltz NM, Gibson AL, Janot JM, Kravitz L, Mermier CM, Dalleck LC. Graded Exercise Testing Protocols for the Determination of VO2max: Historical Perspectives, Progress, and Future Considerations. *J Sports Med (Hindawi Publ Corp)*. 2016;2016:3968393.

17. Jeukendrup A, Saris WH, Brouns F, Kester AD. A new validated endurance performance test. *Med Sci Sports Exerc*. 1996;28(2):266–70.

18. Wardenaar FC, Steennis J, Ceelen IJM, Mensink M, Witkamp R, de Vries JHM. Validation of web-based, multiple 24-h recalls combined with nutritional supplement intake questionnaires against nitrogen excretions to determine protein intake in Dutch elite athletes. *Br J Nutr*. 2015;114(12):2083–92.

19. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications, Inc. accelerometer. *Med Sci Sports Exerc*. 1998;30(5):777–81.

20. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. 2007;39(2):175–91.

21. Wilson JM, Marin PJ, RHEA MR, Wilson SMC, Loenneke JP, Anderson JC. Concurrent training: a meta-analysis examining interference of aerobic and resistance exercises. *J Strength Cond Res*. 2012;26(8):2293–307.

22. Coffey VG, Hawley JA. Concurrent exercise training: do opposites distract? *J Physiol*. 2017;595(9):2883–96.

23. Shamim B, Devlin BL, Timmins RG, et al. Adaptations to Concurrent Training in Combination with High Protein Availability: A Comparative Trial in Healthy, Recreationally Active Men. *Sports Med*. 2018;48(12):2869–83.
24. American College of Sports Medicine. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. *Med Sci Sports Exerc.* 2009;41(3):687–708.

25. Tarnopolsky M. Protein requirements for endurance athletes. *Nutrition.* 2004;20(7-8):662–8.

26. Snijders T, Res PT, Smeets JSJ, et al. Protein Ingestion before Sleep Increases Muscle Mass and Strength Gains during Prolonged Resistance-Type Exercise Training in Healthy Young Men. *J Nutr.* 2015;145(6):1178–84.

27. Res PT, Groen B, Pennings B, et al. Protein ingestion before sleep improves postexercise overnight recovery. *Med Sci Sports Exerc.* 2012;44(8):1560–9.

28. Bandegan A, Courtney-Martin G, Rafii M, Pencharz PB, Lemon PWR. Indicator amino acid oxidation protein requirement estimate in endurance-trained men 24 h postexercise exceeds both the EAR and current athlete guidelines. *Am J Physiol Endocrinol Metab.* 2019;316(5):E741-E748.
FIGURE LEGENDS

**Figure 1.** \( \text{VO}_{2\text{max}} \) in the PLA (n=26) and PRO (n=30) group. Panel A represents \( \text{VO}_{2\text{max}} \) values before and after the 12-week intervention period. The open symbols with error bars represent means±SD and the grey lines represent individual cases. Panel B represents changes in \( \text{VO}_{2\text{max}} \) over the 12-week intervention period. The open symbols represent individual cases and the black lines represent means±SD. Repeated measures ANOVA indicated an increase in \( \text{VO}_{2\text{max}} \) (time effect, \( P<0.0001 \)), with no differences between groups (time×treatment interaction, \( P=0.50 \)).

**Figure 2.** Time-trial performance, muscular endurance and leg lean mass in the PLA (n=26) and PRO (n=30) group. The open symbols represent individual cases and the black lines represent means±SD. Panel A represents changes in time-trial performance over the 12-week intervention period in the PLA (n=26) and PRO (n=30) group. Repeated measures ANOVA indicated a significant reduction in time to complete the time-trial (time effect, \( P<0.0001 \)), with no differences between groups (time×treatment interaction, \( P=0.22 \)). Panel B represents changes in muscular endurance over the 12-week intervention period in the PLA (n=26) and PRO (n=30) group. Repeated measures ANOVA indicated a significant increase in work completed during 30 reciprocal contractions (time effect, \( P<0.0001 \)), with no differences between groups (time×treatment interaction, \( P=0.84 \)). Panel C represents changes in leg lean mass over the 12-week intervention period in the PLA (n=26) and PRO (n=30) group. Repeated measures ANOVA indicated a significant increase in leg lean mass (time effect, \( P<0.0001 \)), which tended to be greater in the PRO group (time×treatment interaction, \( P=0.073 \)).
Figure 1

(A) VO₂max (mL min⁻¹ kg⁻¹)

(B) Change in VO₂max (mL min⁻¹ kg⁻¹)

Pre, Post, PLA, PRO
Figure 2

A. Change in Time Trial Time to Completion (s)

B. Change in Total Work 30 Reciprocal Contractions (kJ)

C. Change in Leg Lean Mass (kg)
Table 1: Participants’ characteristics before and after 12 weeks of endurance exercise training in healthy young males receiving either placebo or protein supplementation

|                      | PLA (n=26) |                       | PRO (n=30) |                       | P value       |
|----------------------|------------|------------------------|------------|------------------------|---------------|
|                      | Pre        | Post                   | Change     | Pre                    | Post          | Change       | Time     | Time x treatment |
| Age (y)†             | 28±6       | 26±6                   |            |                        |               |              | 0.13     | 0.11               |
| Body mass (kg)       | 82.0±9.6   | 81.2±9.7               | -0.8±1.9   | 79.7±13.9              | 79±7±13.1     | 0.0±1.8      | 0.24     | 0.12               |
| Height (m)           | 1.84±0.07  | 1.84±0.07              | 0.00±0.13  | 1.83±0.08              | 1.83±0.08     | 0.00±0.01    | 0.36     | 0.36               |
| BMI (kg·m⁻²)         | 24.3±2.3   | 24.1±2.5               | -0.2±0.5   | 23.8±2.9               | 23.8±2.7      | 0.0±0.5      | 0.097    | 0.079             |
| SBP (mmHg)           | 121±11     | 118±7                  | -3±8       | 117±11                 | 114±10        | -2±9         | 0.027    | 0.72               |
| DBP (mmHg)           | 67±6       | 66±4                   | -1±5       | 65±7                   | 63±6          | -2±6         | 0.13     | 0.33               |
| LM (kg)              | 59.0±6.6   | 58.9±6.6               | -0.1±1.1   | 57.4±8.9               | 57.9±8.4      | 0.5±1.1      | 0.097    | 0.079             |
| Leg LM (kg)          | 19.7±2.7   | 19.9±2.7               | 0.2±0.6    | 19.3±3.0               | 19.9±2.8      | 0.5±0.7      | <0.0001  | 0.073             |
| FM (kg)              | 18.7±5.7   | 18.0±5.4               | -0.7±1.4   | 17.8±5.3               | 17.4±5.0      | -0.4±1.2     | 0.002    | 0.43               |
| FM (%)               | 23.0±5.8   | 22.3±5.5               | -0.7±1.3   | 22.5±4.4               | 22.0±4.2      | -0.6±1.2     | 0.001    | 0.77               |

Data are presented as means±SD and are all normally distributed. BMI: Body mass index, SBP: Systolic blood pressure, DBP: diastolic blood pressure, LM: lean mass, FM: fat mass. Changes in age over time not relevant.
Table 2. Selected workload during the interval exercise sessions (Monday, Friday) and continuous endurance exercise sessions (Wednesday) during 12 weeks of endurance exercise training in healthy young males receiving either placebo or protein supplementation

|                      | PLA (n=25) | PRO (n=28) | P value |
|----------------------|------------|------------|---------|
|                      | Week 1     | Week 6     | Week 12 | Week 1 | Week 6 | Week 12 | Time   | Time x treatment |
| Monday training (W)  | 218±37     | 253±37     | 275±47  | 233±39 | 256±41 | 281±44  | <0.0001 | 0.35        |
| Wednesday training (W)| 153±33 | 164±29     | 180±29  | 156±26 | 172±27 | 186±31  | <0.0001 | 0.59        |
| Friday training (W)  | 286±59     | 283±102    | 341±61  | 278±39 | 288±74 | 346±47  | <0.0001 | 0.68        |

Week 1, week 6 and week 12 data are presented as means±SD. Monday training: 6 x 4-min intervals at a target intensity of 85-90% maximum heart rate (HRmax). Wednesday training: 60-min continuous endurance exercise at a target intensity of 75-80% HRmax. Friday training: 3 sets of 6 x 1-min intervals at a target intensity of 85-90% HRmax. The workload was not registered for 1 participant in the PLA group and 2 participants in the PRO group as they used different cycling ergometers (without power registration) due to their body height.
Table 3. Muscular strength before and after 12 weeks of endurance exercise training in healthy young males receiving either protein or placebo supplementation

|                         | PLA (n=26)                      | PRO (n=30)                      | P value |
|-------------------------|---------------------------------|---------------------------------|---------|
|                         | Pre | Post | Change | Pre | Post | Change | Time | Time x treatment |
| IM<sub>max</sub> (Nm)   | 257±46 | 264±48 | 7±29 | 271±52 | 262±44 | -10±21 | 0.75 | **0.015** |
| IK<sub>maxEX 90°·s<sup>-1</sup></sub> (Nm) | 292±63 | 295±63 | 3±22 | 288±52 | 288±45 | 0±21 | 0.65 | 0.58 |
| IK<sub>maxFL 90°·s<sup>-1</sup></sub> (Nm) | 205±41 | 211±44 | 5±14 | 211±37 | 217±40 | 6±21 | **0.025** | 0.89 |
| IK<sub>maxEX 180°·s<sup>-1</sup></sub> (Nm) | 441±90 | 451±101 | 11±41 | 418±62 | 432±57 | 14±33 | **0.017** | 0.74 |
| IK<sub>maxFL 180°·s<sup>-1</sup></sub> (Nm) | 350±69 | 360±74 | 10±23 | 350±69 | 360±67 | 10±30 | **0.007** | 0.99 |

Data are presented as means±SD and are normally distributed. IM<sub>max</sub>: Maximal isometric torque at 60° angle, IK<sub>maxEX</sub> and FL: Maximal isokinetic extension and flexion at 90°·s<sup>-1</sup> and 180°·s<sup>-1</sup>.
Table 4. Nutritional intake during 12 weeks of endurance exercise training in healthy young males receiving either placebo or protein supplementation

|                      | PLA (n=26) |                      | PRO (n=30) |                      | P value |
|----------------------|------------|----------------------|------------|----------------------|---------|
|                      | Pre        | Week 6               | Week 12    | Pre                  | Week 6  | Week 12    | Time          | Time x treatment |
| Energy (MJ) \(^1\)   | 10.22±2.96 | 10.98±2.77           | 10.70±2.34 | 10.45±3.44           | 10.75±2.45 | 10.78±2.54 | 0.14          | 0.91            |
| Energy (kcal) \(^1\) | 2441±706   | 2621±662             | 2555±559   | 2495±821             | 2567±586  | 2576±607   | 0.14          | 0.91            |
| Energy % protein \(^1\) | 17.3±4.3  | 15.3±3.3             | 15.2±3.0   | 16.0±3.9             | 20.1±3.6  | 19.6±3.1   | 0.066         | <0.0001         |
| Protein absolute (g) \(^1\) | 102±34    | 100±31               | 96±27      | 96±32                | 125±21    | 124±26     | <0.0001       | <0.0001         |
| Protein relative (g·kg\(^{-1}\)) \(^1\) | 1.25±0.41  | 1.23±0.39            | 1.19±0.31  | 1.21±0.35            | 1.60±0.27 | 1.58±0.31  | <0.0001       | <0.0001         |
| Protein excluding supplement (g·kg\(^{-1}\)) \(^1\) | 1.25±0.41  | 1.22±0.39            | 1.18±0.31  | 1.21±0.35            | 1.10±0.23 | 1.08±0.29  | 0.12          | 0.70            |
| Energy % carbohydrate | 42.2±4.7   | 44.5±5.4             | 45.7±4.4   | 43.1±8.4             | 41.4±6.1  | 40.1±5.9   | 0.95          | <0.0001         |
| Carbohydrate absolute (g) | 255±79    | 287±65               | 291±68     | 267±102              | 265±73    | 257±71     | 0.24          | 0.073           |
| Carbohydrate relative (g·kg\(^{-1}\)) \(^1\) | 3.14±1.01  | 3.55±0.86            | 3.64±0.96  | 3.42±1.37            | 3.40±1.05 | 3.31±1.06  | 0.051         | 0.091           |
| Carbohydrate excluding supplement (g·kg\(^{-1}\)) \(^1\) | 3.14±1.01  | 3.12±0.84            | 3.20±0.94  | 3.42±1.37            | 3.36±1.05 | 3.27±1.05  | 0.96          | 0.71            |
| Energy % fat          | 34.5±4.3   | 31.7±5.6             | 32.0±6.1   | 34.7±6.7             | 31.6±6.9  | 33.0±5.7   | **0.0041**   | 0.83            |
| Fat absolute (g) \(^1\) | 96±33      | 93±32                | 91±26      | 99±42                | 91±30     | 95±29      | 0.45          | 0.77            |
| Fat relative (g·kg\(^{-1}\)) | 1.18±0.43  | 1.15±0.41            | 1.14±0.37  | 1.24±0.41            | 1.15±0.36 | 1.22±0.42  | 0.59          | 0.75            |

Pre, week 6 and week 12 data are presented as means±SD. \(^1\)Non-normally distributed data were logarithmically transformed prior to analysis.
Supplemental Figure 1. CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials.
**Supplemental Table.** Estimated mean differences and effect sizes for performance outcomes and body mass in response to 12 weeks of endurance exercise training in healthy, young males receiving either protein or placebo supplementation.

|                      | PLA change (n=26) | PRO change (n=30) | Mean difference (95% CI) | Effect size (95% CI) |
|----------------------|-------------------|-------------------|--------------------------|---------------------|
| VO\textsubscript{2}\text{max} (L·min\textsuperscript{-1}) | 0.35±0.18         | 0.41±0.17         | 0.06 (-0.04 to 0.15)     | 0.33 (-0.20 - 0.86) |
| VO\textsubscript{2}\text{max} (mL·min\textsuperscript{-1}·kg\textsuperscript{-1}) | 5±3               | 5±2               | 0.46 (-0.91 to 1.83)     | 0.18 (-0.35 - 0.71) |
| W\text{max} (W)      | 30±17             | 39±16             | 8.63 (-0.15 to 17.4)     | 0.53 (-0.006 - 1.06) |
| W\text{max} (W·kg\textsuperscript{-1}) | 0.42±0.24         | 0.50±0.25         | 0.081 (-0.05 to 0.21)    | 0.33 (-0.20 - 0.86) |
| HR\text{max} (bpm)\textsuperscript{1} | 0±5               | 0±5               | -0.023 (-2.84 to 2.79)   | -0.005 (-0.55 - 0.54) |
| RER\text{max}        | -0.02±0.06        | -0.02±0.05        | -0.0015 (-0.03 - 0.03)   | -0.029 (-0.55 - 0.50) |
| Time-trial time (s)  | -132±68           | -165±100          | -33.7 (-80.3 to 12.8)    | -0.39 (-0.92 - 0.14) |
| Time-trial mean output (W) | 34±16          | 42±20             | 7.93 (-1.92 to 17.8)     | 0.43 (-0.099 - 0.96) |
| Time-trial mean output (W·kg\textsuperscript{-1}) | 0.46±0.23         | 0.54±0.31         | 0.081 (-0.07 to 0.23)    | 0.29 (-0.24 - 0.82) |
| 30IK total work (kJ) | 170±173           | 181±225           | 11.3 (-97.7 to 120.2)    | 0.056 (-0.47 - 0.581) |
| LM (kg)              | -0.1±1.1          | 0.5±1.1           | 0.52 (-0.06 to 1.09)     | 0.48 (-0.053 - 1.01) |
| Leg LM (kg)          | 0.2±0.6           | 0.5±0.7           | 0.32 (-0.03 to 0.66)     | 0.49 (-0.042 - 1.02) |
| FM (kg)              | -0.7±1.4          | -0.4±1.2          | 0.28 (-0.42 to 0.98)     | 0.21 (-0.31 - 0.74) |
| FM (%)               | -0.7±1.3          | -0.6±1.2          | 0.097 (-0.57 to 0.76)    | 0.079 (-0.45 - 0.60) |

Data are presented as change POST-PRE mean±SD, estimated mean difference between interventions with 95% confidence interval (CI), and effect size with 95% CI. VO\textsubscript{2}\text{max}: Maximum oxygen uptake, W\text{max}: Maximal power, HR\text{max}: Maximal heart rate, RER: Respiratory exchange ratio; CO\textsubscript{2}\text{max}/VO\textsubscript{2}\text{max}. LM: lean mass, FM: fat mass. \textsuperscript{1}Due to technical failure HR\text{max} data are shown for n=23 in the PLA group.
**Supplemental Table.** Habitual physical activity level during 12 weeks of endurance exercise training in healthy young males receiving either placebo or protein supplementation

|                      | PLA (n=26)          | PRO (n=29)          | P value     |
|----------------------|---------------------|---------------------|-------------|
|                      | Pre  | Week 6 | Week 12 | Pre  | Week 6 | Week 12 | Time | Time x treatment |
| Sedentary (%)        | 62.8±6.2 | 61.3±5.1 | 59.9±7.6 | 63.7±6.4 | 64.8±7.4 | 65.1±8.8 | 0.60 | 0.054            |
| Light (%)            | 25.1±3.6 | 26.0±3.8 | 25.7±3.7 | 24.9±4.3 | 23.7±4.8 | 23.7±5.7 | 0.82 | 0.065            |
| Moderate to vigorous | 12.1±3.6 | 12.7±2.6 | 13.0±3.2 | 11.4±2.8 | 11.5±3.4 | 10.9±3.4 | 0.68 | 0.13             |

Pre, week 6 and week 12 data are presented as means±SD and are all normally distributed. Week 6 data were missing from 1 participant in the PRO group.